Shots: Novartis gets an exclusive WW right to develop and commercialize therapeutic applications for FAP assets including FAPI-46 and FAPI-74 under its collaboration with iTheranostics, which is an affiliate of […]readmore
Tags : In-Licenses
Shots: BieGene to receive $650M up front, $1.55M as milestones along with royalties and retain rights to Tislelizumab in China & other countries. BeiGene has the option to co-detail Tislelizumab […]readmore
Shots: Pfizer to receive Axsome’s common shares of ~$8M, $3M in cash as upfront, ~$323M regulatory & commercial milestones and royalties in sales of the therapies and has right of […]readmore
Pharma
Bausch Health In-Licenses Clearside’s Xipere (triamcinolone acetonide suprachoroidal injectable suspension)
Shots: Clearside to receive ~$20M prior to launch including an up front and is eligible to receive commercial & regulatory milestones on approval of Xipere for an additional indication and […]readmore